Key takeaways for Massachusetts
- • Insulin resistance is not a labeled FDA indication for any GLP-1.
- • Improvements typically substantial (30-50% HOMA-IR reduction).
- • Treat via parent diagnosis (obesity, PCOS, T2D, prediabetes).
- • MassHealth coverage rules apply for Insulin Resistance patients in Massachusetts — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Insulin Resistance
There is no FDA indication for insulin resistance as a standalone diagnosis — it is a physiological state, not a labeled disease. GLP-1 therapy improves insulin sensitivity through weight loss, slowed gastric emptying, glucagon suppression, and beta-cell function preservation. Evidence grade: B. Patients with insulin resistance are typically treated via comorbid diagnoses (obesity, prediabetes, PCOS, T2D). HOMA-IR scores typically improve 30-50% with sustained semaglutide or tirzepatide therapy.
Massachusetts-specific context
Massachusetts has telehealth access concentrated in Boston, Worcester, Springfield metros, with additional reach to Cambridge and Lowell. Mass General Brigham, Beth Israel Deaconess, Boston Children's is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.mass.gov/orgs/department-of-public-health.
Massachusettstelehealth & pricing rules
- • Massachusetts requires a live video consultation before a GLP-1 prescription.
- • Massachusetts allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Massachusetts: ~$335/mo (compounded options often lower, brand higher).